ESOPHAGEAL ADENOCARCINOMA

This study tests whether a new drug called zanidatamab, combined with chemotherapy and sometimes another drug (tislelizumab), works better than the current standard treatment for advanced HER2-positive stomach and esophageal cancers. About 920 adults whose cancer has spread or ca…

This early-phase trial tests whether giving chemoradiation plus the immunotherapy drug pembrolizumab, followed by pembrolizumab and lenvatinib before surgery, can kill more cancer cells in people with esophageal or gastroesophageal junction cancer that hasn't spread. The study in…

This phase 2 trial tests whether taking aspirin can prevent Barrett's esophagus from returning after it has been successfully removed with radiofrequency ablation. Researchers will measure levels of a protein linked to Barrett's in tissue samples from 21 participants over 12 mont…

This study looks at whether adding two immunotherapy drugs, nivolumab and ipilimumab, to standard chemotherapy and radiation helps people with esophageal or gastroesophageal junction cancer before and after surgery. About 278 adults with stage II to IVA cancer will take part. The…

This phase 2 trial is testing whether adding the drug neratinib to a standard combination of chemotherapy, trastuzumab, and pembrolizumab can shrink tumors in people with HER2-positive gastroesophageal cancers. The study includes 8 participants and aims to measure how many respon…

This phase 3 study tests whether a new combination of two immunotherapy drugs (domvanalimab and zimberelimab) plus chemotherapy works better than the current standard (nivolumab plus chemotherapy) for people with advanced stomach, gastroesophageal junction, or esophageal cancer t…

This study tests whether combining new drugs with or without chemotherapy can safely control advanced stomach, GEJ, or esophageal cancer. About 332 adults with inoperable or metastatic disease will receive different treatment combinations. The goal is to find more effective optio…

This treatment program tests a personalized cell therapy for people with advanced pancreatic or colorectal cancers that have a specific genetic mutation (KRAS G12D). Patients' own immune cells are collected, genetically engineered to recognize and attack the cancer, and then infu…

This study tests a new medicine called raludotatug deruxtecan in about 160 adults with advanced gastrointestinal cancers (pancreatic, bile duct, gallbladder, colorectal, stomach, or gastroesophageal junction). The drug is designed to attach to cancer cells and deliver a treatment…

This study is for people with HER2-positive esophageal or gastroesophageal junction cancer who have already completed chemoradiation and surgery. The goal is to see if adding a year of treatment with trastuzumab deruxtecan (Enhertu) plus nivolumab is safe and helps prevent the ca…

This early-phase trial tests a freezing treatment called cryotherapy, given before and during standard chemoradiation, for people with locally advanced esophageal cancer. The main goal is to find the safest number of cryotherapy sessions. Researchers will also check if the freezi…

This study tests a new drug called futibatinib combined with standard immunotherapy and chemotherapy in people with advanced esophageal or pancreatic cancer. The goal is to see if the combination can shrink tumors and control the disease. About 53 adults who have not had prior tr…

This pilot trial tests whether using a patient's genetic profile to determine the dose of irinotecan (a chemotherapy drug) can improve outcomes for people with advanced stomach or esophageal cancer. The study combines chemotherapy before and after surgery, with the goal of increa…

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy and radiation can help people with a certain type of esophageal cancer. The trial involves 42 adults whose cancer has not spread far but is locally advanced. The main goal is to see if t…

This phase 3 trial compares a new drug, MK-2870, against standard treatments for people with advanced stomach, gastroesophageal junction, or esophageal cancer that has spread and not responded to prior therapies. About 450 participants will be randomly assigned to receive either …

This study is testing a drug called tucatinib combined with other cancer medicines (trastuzumab, chemotherapy, and pembrolizumab) in people with HER2-positive cancers of the digestive system. The main goals are to find safe doses and see what side effects occur. About 40 adults w…

This early-phase trial tests a new approach for people with locally advanced esophageal cancer. Before surgery, patients receive proton beam radiotherapy along with two chemotherapy drugs (carboplatin and paclitaxel). The main goal is to find the safest dose and see how well pati…

This early-phase trial is testing a new treatment called LB1908, which uses a patient's own immune cells (T-cells) that have been modified in the lab to recognize and attack cancer cells that have a protein called claudin 18.2 on their surface. The study includes up to 56 adults …

This study tests adding the immunotherapy drug durvalumab to standard chemoradiation for people with esophageal or gastroesophageal junction cancer. About 64 participants will receive the combination to see if it is safe and effective. The goal is to improve cancer control withou…

This study is testing a simple, less invasive way to detect Barrett's esophagus and esophageal cancer using a sponge on a string. Participants swallow the sponge, which collects cells from the esophagus. Researchers will analyze these cells to develop a lab test that can spot ear…

This study tests a device called Endosign, which is a sponge on a string that patients swallow to collect cells from the esophagus. The goal is to see if this simple, non-sedation method can provide good enough samples to replace regular endoscopies for monitoring Barrett's esoph…

This study looks at whether a simple, swallowable device can help screen for esophageal cancer in rural Oregon, where getting a traditional endoscopy is hard. About 110 adults with chronic heartburn and other risk factors will try the device at their local clinic. Researchers wan…

This study collects blood and tissue samples from 1,000 adults with Barrett's esophagus or esophageal cancer during their routine endoscopy. The goal is to build a biorepository that links clinical data with specimens, enabling future research into these conditions. Participants …

This study looks at how the immunotherapy drug nivolumab is used in routine care for adults with advanced cancers of the esophagus, gastroesophageal junction, or stomach. Researchers will analyze data from a Dutch cancer registry to see how long people live after starting nivolum…

This study aims to find early DNA changes in blood and esophageal tissue that could signal a higher risk of developing esophageal cancer. Researchers are studying 600 people with gastroesophageal reflux, Barrett's esophagus, or esophageal cancer who are already scheduled for an u…

This study is testing whether an artificial intelligence (AI) model can help doctors better detect, diagnose, and treat esophageal cancer. Researchers will feed de-identified data from 12,000 patients receiving routine care into the AI and compare its recommendations to standard …

This study reviews medical records from 230 adults with stomach or esophagus cancer that spread to the brain. Researchers want to see which local treatments (like surgery or radiation) worked best and how long patients lived. The goal is to gather information to help doctors make…

This observational study collects blood and tumor tissue samples from people with gastroesophageal cancer to study genetic changes that may cause resistance to immunotherapy. It does not involve any treatment or experimental drugs. The goal is to identify new targets for future i…